Mepolizumab effective in Allergic and Non-Allergic Asthma: Study
Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma suggests a new study published in the Annals of Allergy, Asthma and Immunology.
Eosinophilia provides a common denominator for overlapping allergic and non-allergic asthma phenotypes and offers a basis for the efficacy of mepolizumab. While the efficacy and safety of mepolizumab in severe asthma are well-documented, comparative effectiveness data among allergic and non-allergic phenotypes is limited. This study compared the impact of treatment with mepolizumab on patients with allergic versus non-allergic asthma.
This was a retrospective cohort study using administrative claims data from Optum Research Database. The study population included patients with asthma (>=6 years) initiated on mepolizumab between January 2016–December 2019. The asthma exacerbation rate and OCS use were assessed in both the 12 months before (baseline period) and 12 months following (follow-up period) mepolizumab initiation. Allergic status was ascertained using diagnosis codes, medication use and lab test results.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.